GlassScriptPhysician profile
Arthur L Poch
NPI 1831187301
$2,288.62
in general payments reported to CMS, 2019-2025
22 companies · $426 in 2025
The $426 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $115 · 2021: $182 · 2022: $405 · 2023: $516 · 2024: $418 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.46 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.46 | 2021-2025 | |
| Genzyme Corporation | $216.23 | 2022-2025 | |
| Celgene Corporation | $179.38 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $145.05 | 2024 | Voquezna |
| Janssen Biotech, INC. | $135.56 | 2019-2024 | Stelara |
| Gilead Sciences, INC. | $125.00 | 2025 | Vemlidy |
| Janssen Scientific Affairs, LLC | $124.47 | 2019 | |
| Perspectum Diagnostics LTD | $123.35 | 2023 | Livermultiscan |
| Takeda Pharmaceuticals U.S.A., INC. | $117.97 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.10 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $81.07 | 2023 | Zeposia |
| Olympus America INC. | $52.55 | 2025 | Evis Exera III Video System Center, Evis Exera II Ultrasound Gastrovideoscope |
| Qol Medical, LLC | $44.72 | 2023 | Sucraid |
| Pfizer INC. | $33.54 | 2020-2023 | |
| Medtronic, INC. | $27.41 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.32 | 2022 | |
| Covidien LP | $17.53 | 2019 | |
| Ardelyx, INC. | $16.18 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Lilly USA, LLC | $16.03 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $14.62 | 2023 | Ocaliva |
| Amag Pharmaceuticals, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Poch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.